ReviewReproductive biology and endocrinology : RB&E2022
Therapeutic options for premature ovarian insufficiency: an updated review.
Review in Reproductive biology and endocrinology : RB&E, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 60 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 3 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Acupoint stimulation methods for premature ovarian insufficiency: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2025Pooled it
- The effect of ovarian response parameters and the synergistic effect of assisted reproduction of poor ovarian response treated with platelet rich plasma: systematic review and meta-analysis.BMC women's health · 2024Pooled it
- The landscape of genetic variations in non-syndromic primary ovarian insufficiency in the MENA region: a systematic review.Frontiers in endocrinology · 2023Pooled it
- Effect of fennel extract on Anti-Müllerian Hormone and sonographic indices in infertile women with occult premature ovarian insufficiency: a randomized controlled clinical trial.BMC complementary medicine and therapies · 2025Trial
- Bisphenol F-Associated Repeated Breeding Syndrome in Cows: Epidemiological Evidence and Protective Effects of Phillyrin Against Granulosa Cell Injury.Veterinary sciences · 2026Article
- Epigenetic regulation by DNA methylation in PCOS and POI: mechanisms of ovarian dysfunction and implications for clinical research.Journal of ovarian research · 2026Review
- Primary Ovarian Insufficiency: Molecular Mechanisms and the Role of MicroRNAs.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- From Genes to Lives: Integrating the Complexities of Primary Ovarian Insufficiency.International journal of molecular sciences · 2026Review
- Ameliorative effect of pomegranate peel extract nanoparticles and ovarian stem cells-derived exosomes on cyclophosphamide-induced premature ovarian insufficiency.Biological research · 2026Article
- Review
- Follicular Klotho in the Ovarian Microenvironment: Exploring Its Role in IVF Outcome Prediction.Medicina (Kaunas, Lithuania) · 2026Article
- Biomaterials for Reproductive Restoration: Translating Engineering Innovations.Biomaterials research · 2026Review
- Preventing ovarian aging: from redox-targeted strategies to extracellular vesicle-based therapies.Frontiers in aging · 2026Review
- miR-379-5p promotes ovarian granulosa cell apoptosis in primary ovarian insufficiency by targeting KNDC1 and PEG10.Frontiers in genetics · 2026Article
- Rutin rescues oocyte developmental competence in primary ovarian insufficiency by restoring mitophagy and suppressing pyroptosis.Frontiers in cell and developmental biology · 2026Article
- Vitamin B6 promotes the activation of primordial follicles through the PI3K/Akt signaling pathway.Journal of ovarian research · 2025Article
- Causal effects of ferroptosis-related traits on ovarian dysfunction: insights from integrating genome-wide Mendelian randomization, DNA methylation, gene expression, and proteome.Journal of ovarian research · 2025Article
- The implications of LncRNAs and premature ovarian insufficiency.Journal of ovarian research · 2025Review
- Oxidative Stress-Telomere Axis in IVF: Molecular Mechanisms, Biomarkers, and Clinical Translation.International journal of molecular sciences · 2025Review
- Managing the negative regulation of Sirtuins in a murine model of premature ovarian failure: focusing on the key roles of antioxidants.Journal of ovarian research · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
Primary ovarian insufficiency (POI) is a rare gynecological condition. This disease causes menstrual disturbances, infertility, and various health problems. Historically, hormone replacement therapy is the first-line treatment for this disorder. Women diagnosed with POI are left with limited therapeutic options. In order to remedy this situation, a new generation of therapeutic approaches, such as in vitro activation, mitochondrial activation technique, stem cell and exosomes therapy, biomaterials strategies, and platelet-rich plasma intra-ovarian infusion, is being developed. However, these emerging therapies are yet in the experimental stage and require precise design components to accelerate their conversion into clinical treatments. Thus, each medical practitioner bears responsibility for selecting suitable therapies for individual patients. In this article, we provide a timely analysis of the therapeutic strategies that are available for POI patients and discuss the prospects of POI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.